<DOC>
	<DOCNO>NCT00017927</DOCNO>
	<brief_summary>This study examine effect pegvisomant growth hormone excess patient McCune-Albright syndrome ( MAS ) . Patients disease polyostotic fibrous dysplasia-a condition area normal bone replace fibrous growth similar scar tissue , abnormal skin pigmentation ( birth mark ) precocious ( early ) puberty . About 10 percent patient excess growth hormone ( GH ) . GH stimulate production another hormone call insulin-like growth factor 1 ( IGF-1 ) . Together , GH IGF-1 affect bone growth . The excess hormone MAS cause overgrowth bone face , hand foot , excess sweating , increase height . Pegvisomant synthetic drug bind cell receptor GH would normally bind , thus prevent naturally occur hormone stimulate IGF-1 bone growth normally would . This study see pegvisomant reduce blood level IGF-1 mitigate effect growth hormone excess , include bone pain , bone turnover , hand foot swell sweating , abnormal level relate hormone . Patients screen polyostotic fibrous dysplasia MAS NIH protocol 98-D-0145 found MAS excess growth hormone eligible 36-week study . The screen protocol include history physical examination , blood urine test , hearing , eye dental examination , pain physical function evaluation , endocrine bone screening test , various bone image study , include magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan bone biopsy patient 6 year old . Participants current study receive daily injection either pegvisomant placebo ( inactive substance ) 12 week , follow 6-week `` washout '' period drug . Then , patient receive placebo switch , `` cross , '' receive pegvisomant another 12 week , receive pegvisomant receive placebo . This follow another 6-week washout period . The drug placebo inject skin , similar insulin injection . Blood urine test do begin study repeat every 6 week study end .</brief_summary>
	<brief_title>A Study Effects Pegvisomant Growth Hormone Excess McCune-Albright Syndrome</brief_title>
	<detailed_description>McCune-Albright Syndrome ( MAS ) originally describe triad polyostotic fibrous dysplasia bone , cafe-au-lait skin pigmentation precocious puberty . Other endocrine abnormality identify disease . Growth hormone ( GH ) excess associate MAS occur approximately 10 % patient . Current therapy MAS involve separate treatment bone endocrine disease . We propose test effectiveness novel GH receptor antagonist , pegvisomant reduce growth hormone excess patient . Secondarily shall also assess impact pegvisomant therapy fibrous dysplastic bone lesion associate disease . The subject patient MAS non-suppressible growth hormone determine standard oral glucose tolerant testing ( OGTT ) elevate insulin-like growth factor-1 ( IGF-I ) . It randomize , blind crossover design . The primary secondary measure efficacy : normalization serum ( IGF-I ) , reduction sign symptom growth hormone excess , net change Insulin-like Growth Factor Binding Protein 3 ( IGFBP-3 ) . The effect pegvisomant fibrous dysplastic bone activity patient determined net change level bone turnover marker .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrous Dysplasia , Polyostotic</mesh_term>
	<mesh_term>Fibrous Dysplasia Bone</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis PFD/MAS require Protocol 98D0145 Growth hormone excess determine nonsuppressible serum growth hormone oral glucose tolerance test ( OGTT ) . The OGTT parameter serum GH great 2.0 ng/ml 60 minute oral load 75g glucose . Two consecutive duplicate measurement serum IGFI level least 1.3 time great upper limit normal ( age sex adjust accord laboratory normal range ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>McCune-Albright Syndrome</keyword>
	<keyword>IGF-1</keyword>
	<keyword>Adenoma</keyword>
	<keyword>Hyperplasia</keyword>
	<keyword>MAS</keyword>
	<keyword>Polyostotic Fibrous Dysplasia</keyword>
	<keyword>PFD</keyword>
</DOC>